The goal of this activity is for learners to be better able to describe whether non-myeloablative related haploidentical bone marrow transplantation (BMT) with thiotepa and post-transplant cyclophosphamide (PTCy) achieves 2-year event-free survival (EFS: no graft failure or death) of >80%, based on an international multicenter phase 2 clinical trial with 70 evaluable participants (median age 19.1 years) based on the conditioning protocol.
- Provider:Medscape, LLC
- Activity Link: https://www.medscape.org/viewarticle/1001202
- Start Date: 2024-06-20 05:00:00
- End Date: 2024-06-20 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Journal-based CE
- CME Finder Type: Other
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all
- Specialty: Adolescent Medicine, Hematology, Internal Medicine, Medical Oncology
Subscribe
Login
0 Comments
Oldest